SCHEMBL1036207

SCHEMBL1036207

COC(=O)COCCCCN1C(=O)CCC1CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ PTGER4 P35408 6/20 0.38
▸ PTGER3 P43115 3/20 0.33
▸ PTGER2 P43116 3/20 0.33
▸ FKBP1A P62942 1/20 0.32
▸ PDK2 Q15119 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1036206 1.00 PTGER4 (0.38) PTGER4PTGER3PTGER2FKBP1APDK2
SCHEMBL24795958 0.82 TP53 (0.38) PTGER3PTGER2FKBP1A
SCHEMBL1401064 0.82 TP53 (0.38) PTGER3PTGER2FKBP1A
SCHEMBL1074993 0.81 PTGER4 (0.41) PTGER4PTGER3PTGER2PDK2
SCHEMBL1074995 0.81 PTGER4 (0.41) PTGER4PTGER3PTGER2PDK2
SCHEMBL3679333 0.80 PDK2 (0.34) PTGER4PTGER3PTGER2PDK2
SCHEMBL27650285 0.80 PTGER4 (0.39) PTGER4PTGER3PTGER2FKBP1A
SCHEMBL10210244 0.80 PTGER4 (0.39) PTGER4PTGER3PTGER2
SCHEMBL6686327 0.79 PTGER4 (0.41) PTGER4PTGER3PTGER2
SCHEMBL6686330 0.79 PTGER4 (0.41) PTGER4PTGER3PTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1638936-B1 3-OXA-8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN INC (US) 2011-01-26 — — EP disclosed
EP-1638936-A1 3-OXA-8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE Allergan, Inc. (US) 2006-03-29 — — EP disclosed
WO-2004108670-A1 3-OXA-8-AZAPROSTAGLANDIN ANALOGS AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE ALLERGAN, INC. (US) 2004-12-16 — — WO disclosed
US-6734206-B1 POTENT OCULAR HYPOTENSIVES THAT ARE PARTICULARLY SUITED FOR THE MANAGEMENT OF GLAUCOMA ALLERGAN, INC. 2004-05-11 — — US disclosed
Send feedback